GreenC bot (talk | contribs) Rescued 1 archive link. Wayback Medic 2.5 |
No edit summary |
||
(6 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description| |
{{Short description|Antihypertensive drug}} |
||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
Line 32: | Line 32: | ||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
||
| ChEMBL = 1398031 |
| ChEMBL = 1398031 |
||
| KEGG = C07511 |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=11 | H=21 | N=1 |
| C=11 | H=21 | N=1 |
||
Line 41: | Line 42: | ||
}} |
}} |
||
'''Mecamylamine''' ([[International nonproprietary name|INN]], [[British Approved Name|BAN]]; or '''mecamylamine hydrochloride''' ([[United States Adopted Name|USAN]]); brand names '''Inversine''', '''Vecamyl'''<ref>{{cite web | url = https://www.drugs.com/mtm/mecamylamine.html | publisher = [[drugs.com]]| title = Mecamylamine | access-date = May 15, 2015}}</ref>) is a [[binding selectivity|non-selective]], [[Noncompetitive inhibition|non-competitive]] [[receptor antagonist|antagonist]] of the [[nicotinic acetylcholine receptor]]s (nAChRs) that was introduced in the 1950s as an [[antihypertensive]] [[drug]].<ref name="pmid19874251">{{cite journal |vauthors=Bacher I, Wu B, Shytle DR, George TP | title = Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders | journal = Expert Opinion on Pharmacotherapy | volume = 10 | issue = 16 | pages = |
'''Mecamylamine''' ([[International nonproprietary name|INN]], [[British Approved Name|BAN]]; or '''mecamylamine hydrochloride''' ([[United States Adopted Name|USAN]]); brand names '''Inversine''', '''Vecamyl'''<ref>{{cite web | url = https://www.drugs.com/mtm/mecamylamine.html | publisher = [[drugs.com]]| title = Mecamylamine | access-date = May 15, 2015}}</ref>) is a [[binding selectivity|non-selective]], [[Noncompetitive inhibition|non-competitive]] [[receptor antagonist|antagonist]] of the [[nicotinic acetylcholine receptor]]s (nAChRs) that was introduced in the 1950s as an [[antihypertensive]] [[drug]].<ref name="pmid19874251">{{cite journal | vauthors = Bacher I, Wu B, Shytle DR, George TP | title = Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders | journal = Expert Opinion on Pharmacotherapy | volume = 10 | issue = 16 | pages = 2709–2721 | date = November 2009 | pmid = 19874251 | doi = 10.1517/14656560903329102 | s2cid = 25690407 }}</ref> In the [[United States]], it was voluntarily withdrawn from the market in 2009 but was brought to market in 2013 as Vecamyl and eventually was marketed by [[Turing Pharmaceuticals]].<ref>{{Cite web | url = http://adisinsight.springer.com/drugs/800014114 | title = Drug Profile: Mecamylamine - Targacept | work = AdisInsight | publisher = Springer Nature Switzerland AG }}</ref><ref>{{Cite web|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204054|title=Drugs@FDA: FDA Approved Drug Products|website=www.accessdata.fda.gov|access-date=2017-10-16}}</ref> |
||
Chemically, mecamylamine is a secondary [[aliphatic]] [[amine]], with a pK<sub>aH</sub> of 11.2<ref name="pmid13476377">{{cite journal |vauthors=Schanker LS, Shore PA, Brodie BB, Hogben CA |title=Absorption of drugs from the stomach. I. The rat |journal= |
Chemically, mecamylamine is a secondary [[aliphatic]] [[amine]], with a pK<sub>aH</sub> of 11.2<ref name="pmid13476377">{{cite journal | vauthors = Schanker LS, Shore PA, Brodie BB, Hogben CA | title = Absorption of drugs from the stomach. I. The rat | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 120 | issue = 4 | pages = 528–539 | date = August 1957 | pmid = 13476377 }}</ref> |
||
==Medical uses== |
|||
==Pharmacology and clinical applications== |
|||
Mecamylamine has been used as an orally-active [[ganglionic blocker]] in treating [[autonomic dysreflexia]] and [[hypertension]],<ref>{{cite book | |
Mecamylamine has been used as an orally-active [[ganglionic blocker]] in treating [[autonomic dysreflexia]] and [[hypertension]],<ref>{{cite book | vauthors = Soine TO | date = 1966 | title = Textbook of Organic Medicinal and Pharmaceutical Chemistry | edition = 5th| veditors = Wilson CO, Gisvold O, Doerge RF | pages = 468–546 | location = Philadelphia | publisher = Lippincott}}</ref> but, like most ganglionic blockers, it is more often used now as a research tool. |
||
Mecamylamine is also sometimes used as an [[antiaddictive]] drug to help people stop smoking tobacco,<ref name="pmid12080428">{{cite journal |vauthors=Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR |title=Mecamylamine (Inversine): an old antihypertensive with new research directions |journal= |
Mecamylamine is also sometimes used as an [[antiaddictive]] drug to help people stop smoking tobacco,<ref name="pmid12080428">{{cite journal | vauthors = Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR | title = Mecamylamine (Inversine): an old antihypertensive with new research directions | journal = Journal of Human Hypertension | volume = 16 | issue = 7 | pages = 453–457 | date = July 2002 | pmid = 12080428 | doi = 10.1038/sj.jhh.1001416 | doi-access = }}</ref> and is now more widely used for this application than it is for lowering blood pressure. This effect is thought to be due to its blocking [[Alpha-3 beta-4 nicotinic receptor|α3β4]] [[nicotinic receptors]] in the brain. It has also been reported to bring about sustained relief from tics in [[Tourette syndrome]] when a series of more usually used agents had failed.{{medcn|date=October 2016}} |
||
In a recent double-blind, placebo-controlled Phase II trial in Indian patients with major depression, (''S'')-mecamylamine (TC-5214) appeared to have efficacy as an [[Augmentation (psychiatry)|augmentation]] therapy. This is the first substantive evidence that shows that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties.<ref name="pmid19040552">{{cite journal |
In a recent double-blind, placebo-controlled Phase II trial in Indian patients with major depression, (''S'')-mecamylamine (TC-5214) appeared to have efficacy as an [[Augmentation (psychiatry)|augmentation]] therapy. This is the first substantive evidence that shows that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties.<ref name="pmid19040552">{{cite journal | vauthors = Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J, Bencherif M | display-authors = 6 | title = TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity | journal = CNS Neuroscience & Therapeutics | volume = 14 | issue = 4 | pages = 266–277 | year = 2008 | pmid = 19040552 | pmc = 6494058 | doi = 10.1111/j.1755-5949.2008.00054.x }}</ref><ref name="pmid17016705">{{cite journal | vauthors = Rabenstein RL, Caldarone BJ, Picciotto MR | title = The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice | journal = Psychopharmacology | volume = 189 | issue = 3 | pages = 395–401 | date = December 2006 | pmid = 17016705 | doi = 10.1007/s00213-006-0568-z | s2cid = 6395092 }}</ref> TC-5214 is currently in Phase III of clinical development as an add-on treatment and on stage II as a monotherapy treatment for major depression. The first results reported from the Phase III trials showed that TC-5214 failed to meet the primary goal and the trial did not replicate the effects that had been encouraging in the Phase II trial.<ref>{{cite web| vauthors = Carroll J |url=http://www.fiercebiotech.com/story/key-aztargacept-depression-drug-flunks-first-phase-iii-test/2011-11-08 |title=Key AZ/Targacept depression drug flunks first Phase III test |date=8 November 2011 |publisher=Fiercebiotech.com |access-date=2011-11-09}}</ref><ref>{{cite web | vauthors = Hirschler B | date = 8 November 2011 | title = AstraZeneca, Targacept drug fails depression test | url = https://www.reuters.com/article/us-astrazeneca-targacept-idINTRE7A71KO20111108 | work = Reuters }}</ref> Development is funded by Targacept and AstraZeneca.<ref>{{cite web|url=http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DDownload-pipeline-summary.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285619440126&ssbinary=true |title=AstraZeneca Pipeline as of the 27th of January 2011 |access-date=2011-11-09}}</ref> It did not produce meaningful, beneficial results on patients as measured by changes on the [[Montgomery-Asberg Depression Rating Scale]] after eight weeks of treatment as compared with placebo. |
||
==Overdose== |
|||
⚫ | The {{LD50}} for the HCl salt<ref>In view of the time period when these data were generated, they presumably refer to the HCl salt of the racemic drug</ref> in mice: 21 mg/kg (i.v.); 37 mg/kg (i.p.); 96 mg/kg (p.o.).<ref>{{cite journal | vauthors = Spinks A, Young EH, Farrington JA, Dunlop D | title = The pharmacological actions of pempidine and its ethyl homologue | journal = British Journal of Pharmacology and Chemotherapy | volume = 13 | issue = 4 | pages = 501–520 | date = December 1958 | pmid = 13618559 | pmc = 1481871 | doi = 10.1111/j.1476-5381.1958.tb00246.x }}</ref> |
||
==Pharmacology== |
|||
(''S'')-(+)-Mecamylamine [[Dissociation constant|dissociates]] more slowly from [[alpha-4 beta-2|α4β2]] and [[alpha-3 beta-4|α3β4]] receptors than does the (''R'')-(−)-[[enantiomer]].<ref name="pmid11303054">{{cite journal |vauthors=Papke RL, Sanberg PR, Shytle RD |title=Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes |journal= |
(''S'')-(+)-Mecamylamine [[Dissociation constant|dissociates]] more slowly from [[alpha-4 beta-2|α4β2]] and [[alpha-3 beta-4|α3β4]] receptors than does the (''R'')-(−)-[[enantiomer]].<ref name="pmid11303054">{{cite journal | vauthors = Papke RL, Sanberg PR, Shytle RD | title = Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 297 | issue = 2 | pages = 646–656 | date = May 2001 | pmid = 11303054 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=11303054 }}</ref> |
||
A large [[QSAR|SAR]] study of mecamylamine and its analogs was reported by a group from Merck in 1962.<ref name = Stone>{{cite journal |vauthors=Stone CA, Torchiana ML, Meckelnberg KL, Stavorski J, Sletzinger M, Stein GA, Ruyle WV, Reinhold DF, Gaines WA, Arnold H, Pfister K|display-authors = |
A large [[QSAR|SAR]] study of mecamylamine and its analogs was reported by a group from Merck in 1962.<ref name = Stone>{{cite journal | vauthors = Stone CA, Torchiana ML, Meckelnberg KL, Stavorski J, Sletzinger M, Stein GA, Ruyle WV, Reinhold DF, Gaines WA, Arnold H, Pfister K | display-authors = 6 | title = Chemistry and Structure-Activity Relationships of Mecamylamine and Derivatives | journal = Journal of Medicinal and Pharmaceutical Chemistry | volume = 91 | issue = 4 | pages = 665–690 | date = July 1962 | pmid = 14061006 | doi = 10.1021/jm01239a001 }}</ref> Another, more recent [[QSAR|SAR]] study was undertaken by Suchocki et al.<ref>{{cite journal | vauthors = Suchocki JA, May EL, Martin TJ, George C, Martin BR | title = Synthesis of 2-exo- and 2-endo-mecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system | journal = Journal of Medicinal Chemistry | volume = 34 | issue = 3 | pages = 1003–1010 | date = March 1991 | pmid = 2002445 | doi = 10.1021/jm00107a019 }}</ref> |
||
A comprehensive review of the pharmacology of mecamylamine was published in 2001.<ref>{{cite journal | |
A comprehensive review of the pharmacology of mecamylamine was published in 2001.<ref>{{cite journal | vauthors = Young JM, Shytle RD, Sanberg PR, George TP | title = Mecamylamine: new therapeutic uses and toxicity/risk profile | journal = Clinical Therapeutics | volume = 23 | issue = 4 | pages = 532–565 | date = April 2001 | pmid = 11354389 | doi = 10.1016/s0149-2918(01)80059-x }}</ref> |
||
==Toxicology== |
|||
⚫ | The {{LD50}} for the HCl salt<ref>In view of the time period when these data were generated, they presumably refer to the HCl salt of the racemic drug</ref> in mice: 21 mg/kg (i.v.); 37 mg/kg (i.p.); 96 mg/kg (p.o.).<ref>{{cite journal | |
||
==History== |
==History== |
||
Mecamylamine was brought to market by [[Merck & Co.]] in the 1950s; in 1996 Merck sold the asset to [[Layton Bioscience]].<ref>{{cite journal| |
Mecamylamine was brought to market by [[Merck & Co.]] in the 1950s; in 1996 Merck sold the asset to [[Layton Bioscience]].<ref>{{cite journal | vauthors = Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR | title = Mecamylamine (Inversine): an old antihypertensive with new research directions | journal = Journal of Human Hypertension | volume = 16 | issue = 7 | pages = 453–457 | date = July 2002 | pmid = 12080428 | doi = 10.1038/sj.jhh.1001416 | doi-access = }}</ref> In 2002, Targacept acquired it from Layton, intending to repurpose it for CNS conditions.<ref>{{cite news|title=Press release: Targacept, Inc. Acquires Marketed Drug To Expand Its CNS Portfolio {{!}} Evaluate|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=86220§ionID=&isEPVantage=no|work=Targacept via Evaluate|date=August 27, 2002}}</ref> |
||
Targacept voluntarily withdrew mecamylamine from the market in 2009<ref>{{cite web|title=Notification letter from Targacept|url=https://www.fda.gov/downloads/Drugs/NewsEvents/UCM167332.pdf|publisher=FDA|date=June 4, 2009}}</ref> for reasons not related to safety or efficacy.<ref>{{cite web|title=Determination That INVERSINE (Mecamylamine Hydrochloride) Tablet and Six Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness|url=https://www.federalregister.gov/documents/2011/07/28/2011-19110/determination-that-inversine-mecamylamine-hydrochloride-tablet-and-six-other-drug-products-were-not|publisher=Federal Register|date=28 July 2011}}</ref> Manchester Pharmaceuticals brought the drug back to market in 2013.<ref>{{cite news|title=Press release: Manchester Announces FDA Approval of Vecamyl|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=487170|work=Manchester Pharamceuticals via Evaluate|date=May 1, 2013}}</ref> [[Retrophin]] acquired Manchester in 2014<ref>{{cite news| |
Targacept voluntarily withdrew mecamylamine from the market in 2009<ref>{{cite web|title=Notification letter from Targacept|url=https://www.fda.gov/downloads/Drugs/NewsEvents/UCM167332.pdf|publisher=FDA|date=June 4, 2009}}</ref> for reasons not related to safety or efficacy.<ref>{{cite web|title=Determination That INVERSINE (Mecamylamine Hydrochloride) Tablet and Six Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness|url=https://www.federalregister.gov/documents/2011/07/28/2011-19110/determination-that-inversine-mecamylamine-hydrochloride-tablet-and-six-other-drug-products-were-not|publisher=Federal Register|date=28 July 2011}}</ref> Manchester Pharmaceuticals brought the drug back to market in 2013.<ref>{{cite news|title=Press release: Manchester Announces FDA Approval of Vecamyl|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=487170|work=Manchester Pharamceuticals via Evaluate|date=May 1, 2013}}</ref> [[Retrophin]] acquired Manchester in 2014<ref>{{cite news| vauthors = Fidler B |title=Retrophin Shares Boom Following Manchester Pharma Buyout|url=http://www.xconomy.com/new-york/2014/02/13/retrophin-shares-boom-following-manchester-pharma-buyout/|work=Xconomy|date=13 February 2014}}</ref> and after [[Martin Shkreli]] was forced out of Retrophin, in 2014 his new company, [[Turing Pharmaceuticals]], acquired the rights to mecamylamine from Retrophin.<ref>{{cite news| vauthors = Fidler B |title=Shkreli Leads $90M Round for New Startup, Turing Pharma {{!}} Xconomy|url=http://www.xconomy.com/new-york/2015/08/10/shkreli-leads-90m-round-for-new-startup-turing-pharma/#|work=Xconomy|date=10 August 2015}}</ref> |
||
==See also== |
== See also == |
||
* [[Bupropion]] |
* [[Bupropion]] |
||
* [[Hyoscine hydrobromide|Scopolamine]] |
* [[Hyoscine hydrobromide|Scopolamine]] |
||
==References== |
== References == |
||
{{Reflist|2}} |
{{Reflist|2}} |
||
Latest revision as of 06:45, 19 April 2024
Clinical data | |
---|---|
Trade names | Inversine, Vecamyl |
AHFS/Drugs.com | Consumer Drug Information |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 40% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.433 |
Chemical and physical data | |
Formula | C11H21N |
Molar mass | 167.296 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Mecamylamine (INN, BAN; or mecamylamine hydrochloride (USAN); brand names Inversine, Vecamyl[1]) is a non-selective, non-competitive antagonist of the nicotinic acetylcholine receptors (nAChRs) that was introduced in the 1950s as an antihypertensive drug.[2] In the United States, it was voluntarily withdrawn from the market in 2009 but was brought to market in 2013 as Vecamyl and eventually was marketed by Turing Pharmaceuticals.[3][4]
Chemically, mecamylamine is a secondary aliphatic amine, with a pKaH of 11.2[5]
Medical uses
Mecamylamine has been used as an orally-active ganglionic blocker in treating autonomic dysreflexia and hypertension,[6] but, like most ganglionic blockers, it is more often used now as a research tool.
Mecamylamine is also sometimes used as an antiaddictive drug to help people stop smoking tobacco,[7] and is now more widely used for this application than it is for lowering blood pressure. This effect is thought to be due to its blocking α3β4 nicotinic receptors in the brain. It has also been reported to bring about sustained relief from tics in Tourette syndrome when a series of more usually used agents had failed.[medical citation needed]
In a recent double-blind, placebo-controlled Phase II trial in Indian patients with major depression, (S)-mecamylamine (TC-5214) appeared to have efficacy as an augmentation therapy. This is the first substantive evidence that shows that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties.[8][9] TC-5214 is currently in Phase III of clinical development as an add-on treatment and on stage II as a monotherapy treatment for major depression. The first results reported from the Phase III trials showed that TC-5214 failed to meet the primary goal and the trial did not replicate the effects that had been encouraging in the Phase II trial.[10][11] Development is funded by Targacept and AstraZeneca.[12] It did not produce meaningful, beneficial results on patients as measured by changes on the Montgomery-Asberg Depression Rating Scale after eight weeks of treatment as compared with placebo.
Overdose
The LD50 for the HCl salt[13] in mice: 21 mg/kg (i.v.); 37 mg/kg (i.p.); 96 mg/kg (p.o.).[14]
Pharmacology
(S)-(+)-Mecamylamine dissociates more slowly from α4β2 and α3β4 receptors than does the (R)-(−)-enantiomer.[15]
A large SAR study of mecamylamine and its analogs was reported by a group from Merck in 1962.[16] Another, more recent SAR study was undertaken by Suchocki et al.[17]
A comprehensive review of the pharmacology of mecamylamine was published in 2001.[18]
History
Mecamylamine was brought to market by Merck & Co. in the 1950s; in 1996 Merck sold the asset to Layton Bioscience.[19] In 2002, Targacept acquired it from Layton, intending to repurpose it for CNS conditions.[20] Targacept voluntarily withdrew mecamylamine from the market in 2009[21] for reasons not related to safety or efficacy.[22] Manchester Pharmaceuticals brought the drug back to market in 2013.[23] Retrophin acquired Manchester in 2014[24] and after Martin Shkreli was forced out of Retrophin, in 2014 his new company, Turing Pharmaceuticals, acquired the rights to mecamylamine from Retrophin.[25]
See also
References
- ^ "Mecamylamine". drugs.com. Retrieved May 15, 2015.
- ^ Bacher I, Wu B, Shytle DR, George TP (November 2009). "Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders". Expert Opinion on Pharmacotherapy. 10 (16): 2709–2721. doi:10.1517/14656560903329102. PMID 19874251. S2CID 25690407.
- ^ "Drug Profile: Mecamylamine - Targacept". AdisInsight. Springer Nature Switzerland AG.
- ^ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 2017-10-16.
- ^ Schanker LS, Shore PA, Brodie BB, Hogben CA (August 1957). "Absorption of drugs from the stomach. I. The rat". The Journal of Pharmacology and Experimental Therapeutics. 120 (4): 528–539. PMID 13476377.
- ^ Soine TO (1966). Wilson CO, Gisvold O, Doerge RF (eds.). Textbook of Organic Medicinal and Pharmaceutical Chemistry (5th ed.). Philadelphia: Lippincott. pp. 468–546.
- ^ Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR (July 2002). "Mecamylamine (Inversine): an old antihypertensive with new research directions". Journal of Human Hypertension. 16 (7): 453–457. doi:10.1038/sj.jhh.1001416. PMID 12080428.
- ^ Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, et al. (2008). "TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity". CNS Neuroscience & Therapeutics. 14 (4): 266–277. doi:10.1111/j.1755-5949.2008.00054.x. PMC 6494058. PMID 19040552.
- ^ Rabenstein RL, Caldarone BJ, Picciotto MR (December 2006). "The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice". Psychopharmacology. 189 (3): 395–401. doi:10.1007/s00213-006-0568-z. PMID 17016705. S2CID 6395092.
- ^ Carroll J (8 November 2011). "Key AZ/Targacept depression drug flunks first Phase III test". Fiercebiotech.com. Retrieved 2011-11-09.
- ^ Hirschler B (8 November 2011). "AstraZeneca, Targacept drug fails depression test". Reuters.
- ^ "AstraZeneca Pipeline as of the 27th of January 2011". Retrieved 2011-11-09.
- ^ In view of the time period when these data were generated, they presumably refer to the HCl salt of the racemic drug
- ^ Spinks A, Young EH, Farrington JA, Dunlop D (December 1958). "The pharmacological actions of pempidine and its ethyl homologue". British Journal of Pharmacology and Chemotherapy. 13 (4): 501–520. doi:10.1111/j.1476-5381.1958.tb00246.x. PMC 1481871. PMID 13618559.
- ^ Papke RL, Sanberg PR, Shytle RD (May 2001). "Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 297 (2): 646–656. PMID 11303054.
- ^ Stone CA, Torchiana ML, Meckelnberg KL, Stavorski J, Sletzinger M, Stein GA, et al. (July 1962). "Chemistry and Structure-Activity Relationships of Mecamylamine and Derivatives". Journal of Medicinal and Pharmaceutical Chemistry. 91 (4): 665–690. doi:10.1021/jm01239a001. PMID 14061006.
- ^ Suchocki JA, May EL, Martin TJ, George C, Martin BR (March 1991). "Synthesis of 2-exo- and 2-endo-mecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system". Journal of Medicinal Chemistry. 34 (3): 1003–1010. doi:10.1021/jm00107a019. PMID 2002445.
- ^ Young JM, Shytle RD, Sanberg PR, George TP (April 2001). "Mecamylamine: new therapeutic uses and toxicity/risk profile". Clinical Therapeutics. 23 (4): 532–565. doi:10.1016/s0149-2918(01)80059-x. PMID 11354389.
- ^ Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR (July 2002). "Mecamylamine (Inversine): an old antihypertensive with new research directions". Journal of Human Hypertension. 16 (7): 453–457. doi:10.1038/sj.jhh.1001416. PMID 12080428.
- ^ "Press release: Targacept, Inc. Acquires Marketed Drug To Expand Its CNS Portfolio | Evaluate". Targacept via Evaluate. August 27, 2002.
- ^ "Notification letter from Targacept" (PDF). FDA. June 4, 2009.
- ^ "Determination That INVERSINE (Mecamylamine Hydrochloride) Tablet and Six Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness". Federal Register. 28 July 2011.
- ^ "Press release: Manchester Announces FDA Approval of Vecamyl". Manchester Pharamceuticals via Evaluate. May 1, 2013.
- ^ Fidler B (13 February 2014). "Retrophin Shares Boom Following Manchester Pharma Buyout". Xconomy.
- ^ Fidler B (10 August 2015). "Shkreli Leads $90M Round for New Startup, Turing Pharma | Xconomy". Xconomy.